About us
We are changing the future of cancer diagnostics
From Jena. For the world.
The founders and managing directors of oncgnostics GmbH are biologist Dr. Alfred Hansel and biochemist Dr. Martina Schmitz. Their vision was to revolutionize cancer diagnostics to be safe and non-invasive. They also aim to improve existing screening programs and lay the foundation for cancers which currently have no screening programs. The two scientists founded oncgnostics GmbH in 2012. To accomplish their vision, they relied on highly informative biomarkers patented by oncgnostics. These are detected using polymerase chain reaction, or PCR for short. Various awards, such as the Thuringian Research Award (2014), the Thuringian Innovation Award (2014 and 2017) and the IQ Innovation Award Central Germany (2017), encouraged the efforts of the founders to develop this technology.
With GynTect®, we want to provide women with a genuine and safe option for clarifying abnormal findings in cervical cancer screening. Because every woman is in an individual situation and needs individual solutions.
We have developed GynTect® to combat one of the most common types of cancer in women. We focus on early cancer detection, because the great thing about cervical cancer is it can be detected in its preliminary stages. Therefore, it makes sense that the best way to fight cervical cancer is before it even develops.
Exceptional results thanks to intensive research
A completely new method was needed to improve cervical cancer screening. We wanted to look directly into the cells and examine their DNA. So we determined certain characteristics in the DNA, so-called epigenetic biomarkers, which typically occur in cervical cancer. These biomarkers are detected in what is known as polymerase chain reaction, also known as PCR.
Various awards, such as the Thuringian Research Award (2014), the Thuringian Innovation Award (2014 and 2017) and the IQ Innovation Award Central Germany (2017), encouraged the efforts of the founders to develop this technology.
Our aim is to detect cancer at an early stage and provide patients with rapid certainty.
You can find out more on our company website:
Order GynTect®
Contact us to get GynTect®
On request, you will receive a free smear test kit, which is accompanied by a treatment contract. Only when we have received the swab sample together with the signed examination request in the laboratory will you pay a cost of 150 Euros.
Do you have any further questions? Please use one of the below contact methods.
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Contact us if you have any further questions:
Picture credits:
About us: Eberhard Schorr/oncgnostics GmbH
From Jena. Für die Welt: Annett Schmitz
Portraits: Eberhard Schorr/oncgnostics GmbH
Exceptional results due to intensive research: Eberhard Schorr/oncgnostics GmbH
Our aim: Eberhard Schorr/oncgnostics GmbH
Contact: Eberhard Schorr/oncgnostics GmbH; Grit Hiersemann